Lewy body dementia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• SNCA 2
• APOE 2
• GBA1 0
• TDP-43 0
• MAPT 0
• APP 0
• BDNF 0
• C9orf72 0
• GLP-1 0
• HDAC 0
• LRRK2 0
• mTOR 0
• PI3K 0
• PINK1 0
• PPAR 0
• STING 0
• TREM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 340 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  K0706 for Patients Diagnosed With Dementia With Lewy Bodies

  NCT03996460· Georgetown University· Updated 8 Jun 2026

  “Interim analysis was performed for 442 patients who completed Part I of the PROSEEK study-(CLR\_18\_06); it did not show evidence of treatment benefit in patients receiving Vodobatinib.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia

  NCT05497817· Mayo Clinic· Updated 17 Nov 2022

  “Study withdrawn and being modified under another protocol”Registry text, quoted unchanged. Source

• Withdrawn

  Biomarkers in Neurodegenerative Diseases

  NCT04055532· University of Minnesota· Updated 12 Nov 2019

  “Lack of regulatory approval”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• VOCALE LBD: Online Peer Support for Caregivers of People With Lewy Body Dementia

  NCT07637097· University of Washington· Source

• Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes

  NCT07604883· International Institute of Molecular and Cell Biology in Warsaw· Source

• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

  NCT07589595· Eli Lilly and Company· Source

• Parkinson's Disease and Movement Disorders Clinical Database

  NCT04997642· University of Pennsylvania· Source

• Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies

  NCT07240805· BioSensics· Source

• tDCS Effect on Psychotic Symptoms in Dementia With Lewy Bodies (DLB), and Impacts on Caregiver Burden

  NCT06785948· Association de Recherche Bibliographique pour les Neurosciences· Source

• Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases

  NCT05326750· Kuopio University Hospital· Source

• Visual Hallucinations in Lewy Body Diseases

  NCT07849413· NYU Langone Health· Source

• Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease

  NCT06846658· Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta· Source

• Dementia With Lewy Bodies: Clinical Symptoms, Biomarkers and Progression

  NCT07629349· Karolinska Institutet· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 3
• Mendelian Randomization Analysis 11
• Gene Expression Profiling 3
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 1
• Proteomics 17
• Mass Spectrometry 2
• Flow Cytometry 1
• Positron-Emission Tomography 20
• Magnetic Resonance Imaging 31
• Machine Learning 6
• Deep Learning 2
• Cohort Studies 29
• Genome-Wide Association Study 16

• Spatiotemporally resolved single-nucleus transcriptomics reveals cellular and regional vulnerability in the midbrain in Parkinson's disease.

  Signal Transduct Target Ther, Oct 2026

• Interrogating DNA methylation associated with Lewy body pathology in a cross brain-region and multi-cohort study.

  Nat Commun, Sept 2026

• Genetic Prioritization of Plasma Proteins Across Dementia Subtypes: A Proteome-Wide Mendelian Randomization and Bayesian Colocalization Analysis.

  Cell Mol Neurobiol, Sept 2026

• Elucidating shared genetic signals between type 2 diabetes and three neurodegenerative dementia phenotypes.

  HGG Adv, Sept 2026

• Refining the link between REM sleep behavior disorder and neurodegeneration: Genetic correlation, Mendelian randomization, and colocalization evidence.

  Medicine (Baltimore), Jul 2026

• Understanding the genetic imperfections of Lewy body dementia.

  Mol Neurodegener, Jul 2026

• Genome wide association study meta-analysis of neuropathologic lesions of Alzheimer's disease and related dementias in a multi-site autopsy cohort.

  PLoS Genet, Jun 2026

• Relationship between mental disorders and non-traumatic cerebral hemorrhage: cross-sectional analysis and mendelian randomization.

  PeerJ, Jun 2026

• The Global Parkinson's Genetics Program (GP2): Advancing genetic discovery and capacity building worldwide.

  J Parkinsons Dis, May 2026

• Cell-type-specific genetic associations in Lewy body dementia identified using single-cell eQTL-based Mendelian randomization.

  Arch Gerontol Geriatr, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.